Business Combinations (Tables)

6 Months Ended

Jun. 30, 2015

NPS Pharma

Business Acquisition [Line Items]

Schedule of Purchase Price Allocation

	Preliminary
	Fair value
	$’M
ASSETS
Current assets:
Cash and cash equivalents	41.6
Short-term investments	67.0
Accounts receivable	33.4
Inventories	89.4
Deferred tax assets	156.3
Other current assets	11.1
	_______________
Total current assets	398.8
Non-current assets:
PP&E	4.8
Goodwill	1,679.4
Other intangible assets
- currently marketed products	4,640.0
- royalty rights (categorized as "Other amortized intangible assets" )	353.0
	_______________
Total assets	7,076.0
	_______________
LIABILITIES
Current liabilities:
Accounts payable and other current liabilities	72.5
Short-term debt	27.4
Non-current liabilities:
Long-term debt, less current portion	78.9
Deferred tax liabilities	1,673.1
Other non-current liabilities	4.5
	_______________
Total liabilities	1,856.4
	_______________
Fair value of identifiable assets acquired and liabilities assumed	5,219.6
Consideration	_______________
Cash consideration paid	5,219.6
	_______________

Business Acquisition, Pro Forma Information

	6 months to	6 months to
	June 30,	June 30,
	2015	2014
	$’M	$’M
	_______________	_______________
Revenues	3,075.9	2,949.0
Net income from continuing operations	526.6	565.7
	_______________	_______________
Per share amounts:
Net income from continuing operations per share - basic	95.9c	96.6c
Net income from continuing operations per share - diluted	95.4c	95.8c
	_______________	_______________

Viropharma

Business Acquisition [Line Items]

Schedule of Purchase Price Allocation

	Acquisition date fair value
	$’M
Identifiable assets acquired and liabilities assumed
ASSETS
Current assets:
Cash and cash equivalents	232.6
Short-term investments	57.8
Accounts receivable	52.2
Inventories	203.6
Deferred tax assets	100.7
Purchased call option	346.7
Other current assets	50.9
	_______________
Total current assets	1,044.5
Non-current assets:
PP&E	24.7
Goodwill	1,655.5
Other intangible assets
- Currently marketed products	2,320.0
- In-Process Research and Development (“IPR&D”)	315.0
Other non-current assets	10.4
	_______________
Total assets	5,370.1
	_______________
LIABILITIES
Current liabilities:
Accounts payable and other current liabilities	122.7
Convertible bond	551.4
Non-current liabilities:
Deferred tax liabilities	603.5
Other non-current liabilities	95.5
	_______________
Total liabilities	1,373.1
	_______________
Fair value of identifiable assets acquired and liabilities assumed	3,997.0
	_______________
Consideration
Cash consideration paid	3,997.0
	_______________